plethora

(redirected from plethoras)
Also found in: Dictionary, Thesaurus, Medical, Legal.

plethora

Pathol obsolete a condition caused by dilation of superficial blood vessels, characterized esp by a reddish face

Plethora

 

an increase in the volume of blood. An increase in the total quantity of blood in the human body is called generalized plethora; localized congestion from blood stasis can also occur in organs, such as the brain or spleen.

plethora

[′pleth·ə·rə]
(medicine)
An excess of blood in an organ or the circulatory system.

plethora

An abundance or excess.
References in periodicals archive ?
Plethora is focused on the development and marketing of products for the treatment of urological disorders.
In April 2009, Plethora and Sciele amended the 2007 US license agreement for PSD502, and as a result, Sciele owns the New Drug Application as well as all US rights to the product.
The revenue interest will be paid by Plethora primarily on revenues derived from sales of ErecAid, PSD502 and PSD510.
Mike Wyllie, CSO of Plethora, commented, "This represents a major milestone in the clinical development program of PSD502, and we expect to report on the outcome later in the year.
Michael Wyllie, Chief Technical Officer, of Plethora stated, "The ability to raise this level of funding in today's financial climate says much about the excellent commercial potential of our products, including Invicorp.
Mike Wyllie, CSO of Plethora, said, "We are clearly delighted with these highly significant results from the European Phase III clinical study and now await the final results from the US study in the first half of 2009.
Plethora Solutions Holdings PLC ("Plethora", AIM: PLE), the developer of specialist products and therapeutics for the treatment and management of urological disorders, today announces that it has secured 4 million pounds in a secured loan from ETV Capital S.
In May 2007, Sciele signed an exclusive licensing agreement with Plethora Solutions to market PSD502 in the U.
Steven Powell, CEO of Plethora, commented, "We are very happy with our collaboration with Inyx, which allows us to progress PSD502 down the path towards Phase III clinical development.